DTx Pharma Acquired by Novartis for CMT1A Therapy
Message From CMTRF CEO: This morning, DTx Pharma announced that it has been acquired by Novartis for an upfront payment of $500 million and additional payments of up to $500 million upon completion of pre-specified milestones. This is a very exciting next step in our...DTx Pharma Video – Using siRNA to Treat Charcot-Marie-Tooth Disease Type 1A
Dr. Arthur Suckow, DTx Pharma Inc. – FALCON
One of the first research teams the CMT Research Foundation (CMTRF) funded was DTx Pharma, Inc., and the project focused on delivery of genetic medicine to the myelinating Schwann cells of the peripheral nerves – a major scientific challenge to effectively...